Ligand Pharmaceuticals LGND EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's EPS (diluted)?
- Ligand Pharmaceuticals (LGND) reported EPS (diluted) of -$0.67 in Q1 2026.
- How has Ligand Pharmaceuticals's EPS (diluted) changed year-over-year?
- Ligand Pharmaceuticals's EPS (diluted) increased by 69.7% year-over-year, from -$2.21 to -$0.67.
- What is the long-term trend for Ligand Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's EPS (diluted) has grown at a 14.3% compound annual growth rate (CAGR), from $3.45 to $5.89.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.